Haemonetics (HAE) Tops Q4 EPS by 2c, provides guidance

Haemonetics (NYSE: HAE) reported Q4 EPS of $1.24, $0.02 better than the analyst estimate of $1.22. Revenue for the quarter came in at $331 million versus the consensus estimate of $330.66 million.

GUIDANCE:

Haemonetics sees FY2026 EPS of $4.70-$5.00, versus the consensus of $4.54.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BioLargo Reports Second Quarter 2026 Results; Revenue Up 12% Sequentially, Gross Margin Expands to 54%
• NVIDIA (NVDA) call put ratio 1.9 calls to 1 put with a focus on 5K contracts of October 160 puts